{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-088584","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.964462+00:00","generated_at":"2026-06-12T01:31:13.079129+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ironwood posts Q2 GAAP net loss of $1.06B on acquisition costs; LINZESS sales +9%","bullets":["GAAP net loss attributable to Ironwood of $1.06B, or $6.84/share diluted, primarily from VectivBio acquisition.","Total revenues $107.4M, up 10% YoY; LINZESS U.S. net sales $270M, +9% YoY.","FDA approved LINZESS for pediatric FC ages 6-17 in June, expanding addressable market.","Acquired VectivBio for apraglutide (SBS-IF); STARS Phase III enrollment complete, data March 2024.","Raised full-year 2023 guidance: LINZESS net sales $1.055-1.075B, Ironwood revenue $435-455M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-088584","json":"https://secwatch.observer/filing/0001104659-23-088584.json","markdown":"https://secwatch.observer/filing/0001104659-23-088584.md","text":"https://secwatch.observer/filing/0001104659-23-088584.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923088584/0001104659-23-088584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923088584/tm2323024d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:31:13.079129+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"657f184ea0a51b778ec222433e6698b12dbde677","claim":"IRONWOOD PHARMACEUTICALS INC reported second quarter 2023 results: revenue $107,382, net income $(1,089,478), EPS $(6.84) per share – basic. Guidance raised.","evidence_excerpt":"position, and grow Ironwood’s leadership within GI.” Second Quarter 2023 Financial Highlights 1 (in thousands, except for per share amounts) 2Q 2023 2Q 2022 Total revenues $ 107,382 $ 97,231 Total operating expenses 2 1,190,521 41,576 GAAP net income (loss) 2 (1,089,478 ) 37,080 GAAP net income (loss) attributable to Ironwood Pharmaceuticals, Inc. 2","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923088584/0001104659-23-088584-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Revenue","value":"$107,382"},{"label":"Net income","value":"$(1,089,478)"},{"label":"EPS","value":"$(6.84) per share – basic"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}